Skip to content
Open access

In Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relapsed/Refractory Large B-Cell Lymphoma.

Aug 2026 · Clinical Lymphoma, Myeloma & Leukemia · Vol 26, pp. 670-688.e2 · 0 citations · 40 references
Medicine

TL;DR

In conclusion, axi-cel provided superior PFS and OS to patients with r/r LBCL compared with allo-HCT, primarily due to lower treatment-related mortality and improved disease control in patients with chemorefractory disease prior to cellular therapy.

Abstract

Background

CD19-directed chimeric antigen receptor (CAR) T-cell therapy has become the preferred cellular immunotherapy for relapsed/refractory (r/r) large B-cell lymphoma (LBCL), whereas allogeneic hematopoietic cell transplantation (allo-HCT) remains a potential salvage option. Comparative real-world data between both approaches are limited. PATIENTS AND

Methods

We conducted a retrospective single-center real-world analysis comparing outcomes of allo-HCT and CD19-directed CAR T-cell therapy with axicabtagene ciloleucel (axi-cel). A total of 187 patients with r/r large B-cell lymphoma (r/r LBCL) were included. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included relapse incidence (RI), non-relapse mortality (NRM), and treatment-related toxicities. Propensity score matching (PSM) was performed to adjust for baseline differences.

Results

Response rates and relapse incidence were comparable between groups. However, NRM was significantly higher after allo-HCT (12% vs. 36%; P = < .001), mainly driven by infections and graft-versus-host disease. Consequently, axi-cel was associated with superior survival, with 12-month PFS of 50.1% versus 33.8% and OS of 60.5% versus 43.2% (both P < .05). These findings were confirmed in subgroup analyses (≥ 3rd line) and propensity score-matched cohorts. Multivariable analyses identified primary refractoriness and poor performance status as adverse prognostic factors, while treatment modality mainly impacted NRM rather than relapse risk.

Conclusion

In conclusion, axi-cel provided superior PFS and OS to patients with r/r LBCL compared with allo-HCT, primarily due to lower treatment-related mortality and improved disease control in patients with chemorefractory disease prior to cellular therapy.

Read PDF

Similar papers

Oct 2026

CAR T-cell therapy for relapsed and refractory B-cell non-Hodgkin lymphoma: a single-centre 5-year real-world experience study at Ghent University Hospital.

BACKGROUND Relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) remains challenging to treat, particularly in patients ineligible for high-dose chemotherapy and autologous stem cell transplantation. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment. AIMS We describe the e...

Julie Vandewiele, Chiel Gharakhani, C. De Vriendt et al. · 0 citations
Open access Oct 2026

Allogeneic anti-CD19 CAR-T therapy demonstrates sustained efficacy and manageable safety in post-allo-HSCT relapsed B-ALL with extramedullary disease

Relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem-cell transplantation (allo-HSCT), particularly with extramedullary disease (EMD), has a dismal prognosis. The efficacy and durability of allogeneic chimeric antigen receptor T cell (allo-CAR-T) therapy in this setting remain...

Rui Liu, Jian Zhang, Ying Li et al. · 0 citations
Open access Oct 2026

Comparative effectiveness of CAR-T cell therapy and CD20xCD3 bispecific antibodies in relapsed/refractory follicular lymphoma: A propensity score–matched real-world analysis.

639 Background: CD20×CD3 bispecific antibodies and chimeric antigen receptor T-cell (CAR-T) therapy have expanded treatment options for relapsed/refractory follicular lymphoma (R/R FL). Although both therapies demonstrate substantial clinical activity, comparative real-world data remain limited. We compared sur...

Navya Pillikunte Doddareddy, Ranjit Sah, G. Sorescu · 0 citations
Review Open access Nov 2026

Efficacy and safety of chimeric antigen receptor T-cell therapy versus standard treatment in hemato-oncology: A systematic review and meta-analysis.

BACKGROUND Chimeric antigen receptor (CAR) T-cell therapy has been compared with established non-CAR T treatments in several hematological malignancies, but the magnitude and consistency of benefit across diseases and comparators remain unclear. We conducted a systematic review and meta-analysis of comparative studies...

Ádám Szilágyi, Petra Varga, G. Agócs et al. · 0 citations
Open access Sep 2026

Outcomes of locally produced donor-derived anti-CD19 chimeric antigen receptor T-cells in relapsed or refractory B-cell acute lymphoblastic leukemia patients

Donor-derived anti-CD19 chimeric antigen receptor T-cell (CAR T-cell) therapy has emerged as one of the most promising treatments for relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). In this retrospective study, we evaluated the safety and efficacy of donor-derived anti-CD19 CAR T cells manufactur...

Supavich Tannumsaeng, U. Anurathapan, Arpatsorn Sermcheep et al. · 0 citations
Open access Nov 2026

Impact of consolidative HSCT after CAR T-cell–induced remission in pediatric relapsed/refractory B-ALL: a single-center retrospective cohort

Whether allogeneic hematopoietic stem cell transplantation (HSCT) is required after chimeric antigen receptor T-cell (CAR-T)–induced remission in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) remains unresolved. We report single-center outcomes of CAR-T therapy with or without subseq...

Zi-Wei Liao, Fei-Mei Kuang, Yuxuan Luo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.